Flecainide acetate is a new synthetic antiarrhythmic drug which is classified as a Vaughan Williams class IC agent.' 2 It has been shown to be effective in the treatment of junctional arrhythmias3 and in certain ventricular arrhythmias,4-6 but there are few published data on its use in atrial arrhythmias. It seems effective in the conversion of atrial fibrillation to sinus rhythm, but is much less effective for terminating atrial flutter. ' We report three patients with atrial tachycardias who were successfully treated by intravenous flecainide and in whom sinus rhythm was maintained with the oral preparation. The electrophysiological effects of flecainide have beenstudied extensively, and in general its effect on conduction is more profound than on refractoriness. In particular, it causes a consistent increase in the PA interval, a measure of the intra-atrial conduction time, by a mean of 22%. Increases in atrial refractoriness have been shown,'0 but these are usually small and fail to reach statistical significance, although Pop et al found a significant increase of 17*5%." In the same report flecainide successfully prevented the induction of atrial tachyarrhythmias by programmed stimulation in nine out of 16 patients studied.
Patients and methods

CASE
Orning reported a single case of chronic atrial tachycardia where temporary suppression of the arrhythmia was achieved by intravenous flecainide. 12 Somani reported the effective suppression of atrial extrasystoles in two out of three patients given flecainide intravenously but found no effect on chronic atrial fibrillation in another two patients.'3 Nathanet al treated 10 patients with paroxysmal atrial fibrillation with intravenous flecainide and produced conversion to sinus rhythm in nine.7 By contrast, in the same report, termination of paroxysmal atrial flutter by intravenous flecainide was achieved in only two out of a further 10 patients, although the atrial rate slowed in all cases and slowing of the ventricular response occurred in nine.
It is of interest that in two cases in the present report tachycardia reversion occurred by progressive slowing until sinus rhythm emerged and resumed control. This is in contrast to the effect of flecainide on junctional re-entrant tachycardias where termination is sudden and where there is a more pronounced effect on the refractoriness of some of the individual tissue components of the junctional re-entrant circuit.3 10 In case 1 flecainide successfully abolished the repetitive atrial ectopic activity, which suggests that it may also selectively suppress the enhanced automaticity of ectopic foci.
The efficacy of flecainide against atrial tachycardias shown by these cases suggests a potential additional use for the drug, although comparative studies are required to define its precise role. 
